Use of ELISPOTS to monitor cloning of AChR-specific T-cells from myasthenia gravis patients

被引：0
|
作者：
Zhang, W [1 ]
Leite, I [1 ]
Kishore, U [1 ]
Water, P [1 ]
Willcox, N [1 ]
机构：
[1] Univ Oxford, Weatherall Inst Mol Med, Neurosci Grp, Oxford, England
来源：
JOURNAL OF NEUROIMMUNOLOGY | 2004年 / 154卷 / 1-2期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
502
引用
收藏
页码：150 / 150
页数：1
相关论文
共 50 条
  • [21] STIMULATION OF SPECIFIC T-CELLS BY HUMAN ACHR ADSORBED TO IMMUNOMAGNETIC PARTICLES
    HAWKE, S
    WILLCOX, N
    HARCOURT, G
    VINCENT, A
    NEWSOMDAVIS, J
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1993, 681 : 288 - 291
  • [22] Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients
    Kordas, Gregory
    Lagoumintzis, George
    Sideris, Sotirios
    Poulas, Konstantinos
    Tzartos, Socrates J.
    PLOS ONE, 2014, 9 (09):
  • [23] The increased expression of CD21 on AchR specified B cells in patients with myasthenia gravis
    Yin, Weifan
    Allman, Windy
    Ouyang, Song
    Li, Yi
    Li, Jing
    Christadoss, Premkumar
    Yang, Huan
    JOURNAL OF NEUROIMMUNOLOGY, 2013, 256 (1-2) : 49 - 54
  • [24] DR-bound peptides isolated from an AChR fragment-pulsed DR4-transfected murine macrophage cell line are recognized by a AChR-specific CD4+ T cell clone derived from a myasthenia gravis patient.
    Verreck, FAW
    Vos, K
    Bontrop, D
    Melchers, L
    Breedveld, FC
    Koning, F
    deVries, RRP
    Willcox, N
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 32 - 32
  • [25] B-CELLS AN T-CELLS DIFFERENTIATION ANTIGENS IN MYASTHENIA-GRAVIS THYMUS
    LEPETIT, JC
    ANTOINE, JC
    POMIER, G
    BOUCHERON, S
    FREYCON, F
    MICHEL, D
    IMMUNOBIOLOGY, 1986, 173 (2-5) : 339 - 340
  • [26] Use of peptide: HLA class II complexes to study specific T cells in myasthenia gravis
    Kishore, U
    Zhang, W
    Corlett, L
    Kelleher, A
    Shiono, H
    Willcox, N
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (02): : 229 - 229
  • [27] CHIMERIC AUTOANTIBODY RECEPTOR (CAAR) T CELLS AS INNOVATIVE TREATMENT OF ACHR ANTIBODY POSITIVE MYASTHENIA GRAVIS
    Von Wardenburg, N.
    Reincke, S. M.
    Homeyer, M. A.
    Bandura, S.
    Lelievre, N.
    Pelz, A.
    Meisel, A.
    Pruess, H.
    HUMAN GENE THERAPY, 2022, 33 (7-8) : A32 - A32
  • [28] SUPPRESSOR T-CELLS IN MYASTHENIA-GRAVIS AND ANTIBODIES TO ACETYLCHOLINE-RECEPTOR
    LISAK, RP
    LARAMORE, C
    LEVINSON, AI
    ZWEIMAN, B
    MOSKOVITZ, AR
    ANNALS OF NEUROLOGY, 1986, 19 (01) : 87 - 89
  • [29] Heterogeneity and immunotherapy of specific T cell clones from myasthenia gravis patients.
    Willcox, N
    Bond, A
    Corlett, L
    Nicolle, MW
    Spack, EG
    Vincent, AC
    NewsomDavis, J
    IMMUNOLOGY, 1996, 89 : SQ65 - SQ65
  • [30] ACETYLCHOLINE RECEPTOR-SPECIFIC T-CELL LINES AND THEIR USE IN FUNCTIONAL ANALYSES OF T-CELLS IN THE IMMUNE PATHOGENESIS OF EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS
    SCHALKE, BCG
    BENNUN, A
    KALIES, I
    COHEN, JR
    KALDEN, JR
    WEKERLE, H
    IMMUNOBIOLOGY, 1982, 162 (4-5) : 414 - 414
12345